John O’Connor
About John J. O’Connor
John J. O’Connor (age 77) is an independent director of LeMaitre Vascular, Inc. and has served on the Board since 2008 . He is a former partner and Vice Chairman of Services at PricewaterhouseCoopers LLP (PwC) and previously led PwC’s U.S. audit practice and the Boston office; the Board designates him as an “audit committee financial expert” based on his public financial accounting expertise . Education includes Suffolk University and executive programs at Harvard Business School (Leadership in Professional Service Firms) and the Tuck School of Business at Dartmouth .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| PricewaterhouseCoopers LLP | Partner (1982–2006); Vice Chairman of Services (Jun 2002–Nov 2006); Leader, U.S. audit practice (Sep 2000–Jun 2002); Managing Partner, Boston office (1995–Sep 2000) | 1982–2006 | Extensive public financial accounting leadership; qualifies as “audit committee financial expert” |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| mTuitive, Inc. | Director | Not disclosed | Clinical data capture/synoptic reporting software |
| Health Data Analytics, Inc. | Director | Not disclosed | Healthcare analytics |
| Corvent Medical, Inc. | Director | Not disclosed | Medical device company |
| Almond Fintech | Director | Not disclosed | Digital payments |
| Aspect Medical Systems | Prior Director | Not disclosed | Prior public company board |
| Abt Associates | Prior Director | Not disclosed | Research/consulting organization |
Board Governance
- Independence: The Board affirmatively determined O’Connor is independent under Nasdaq standards .
- Committee assignments (2024): Audit Committee (Chair); not a member of Compensation or Nominating & Corporate Governance Committees .
- Attendance: In 2024 the Board met seven times; all directors attended at least 75% of Board and applicable committee meetings .
- Audit Committee activity: Met four times plus one unanimous written consent in 2024; O’Connor chairs and is designated as the audit committee financial expert .
- Lead Independent Director: The company combines CEO and Chair roles and does not have a lead independent director .
- Executive sessions: Independent directors typically hold at least one executive session per year, chaired on a rotating basis .
- Say-on-pay context: Stockholders supported executive compensation by >96% at the 2024 Annual Meeting, indicating broad approval of pay practices .
Fixed Compensation
| Component (2024) | Amount (USD) | Notes |
|---|---|---|
| Fees Earned or Paid in Cash | $50,000 | Actual cash compensation received for 2024 |
| Board Annual Retainer (Policy) | $26,000 | Policy schedule for non-employee directors |
| Audit Committee Chair Retainer (Policy) | $20,000 | Policy schedule |
| Audit Committee Member Retainer (Policy) | $6,000 | Policy schedule |
| Compensation Committee Member Retainer (Policy) | $2,500 | Policy schedule |
| Nominating & Corporate Governance Chair Retainer (Policy) | $6,500 | Policy schedule |
| Nominating & Corporate Governance Member Retainer (Policy) | $2,000 | Policy schedule |
O’Connor’s actual 2024 cash fees ($50,000) reflect the company’s policy plus any proration or plan specifics for the year .
Performance Compensation
| Component (2024) | Amount (USD) | Design/Mix | Vesting/Performance Notes |
|---|---|---|---|
| Stock Awards (RSUs/PSUs) | $56,000 | Part of annual director equity grant | PSUs subject to Company performance; RSUs time-based; grant-date fair value per FASB ASC 718 |
| Option Awards | $56,000 | Part of annual director equity grant | Black-Scholes valuation; typical plan terms |
| Annual Equity Grant Policy (Directors) | $170,000 | 50% options, 25% PSUs, 25% RSUs | Eligibility requires ≥6 months of service at grant |
| Outstanding RSUs (as of 12/31/2024) | 966.24 units | Director-level counts | Company-wide director disclosure applies to each current non-employee director |
| Outstanding PSUs (as of 12/31/2024, target) | 1,137.58 units | Director-level counts | Grant-date fair value assuming target; max PSUs value at grant was $51,000 per director |
| Outstanding Options (as of 12/31/2024) | 19,519 | Director-level count | Aggregate outstanding options for O’Connor |
The proxy provides detailed PSU/option accounting treatment, but does not specify director PSU performance metrics; PSUs are performance-based under the equity plan and valued per ASC 718 at grant .
Other Directorships & Interlocks
| Company | Relationship to LMAT | Potential Interlock/Conflict |
|---|---|---|
| Corvent Medical, Inc. | Medical device industry | No specific related-party transactions disclosed with LMAT; general industry adjacency only |
| mTuitive, Health Data Analytics, Almond Fintech | Software/analytics/fintech | No LMAT-related transactions disclosed |
| Aspect Medical Systems (prior) | Prior public company board | Historical; no current LMAT interlock disclosed |
Expertise & Qualifications
- Public company board experience and deep financial/accounting expertise recognized in Board skills matrix and biography .
- Strategic planning, risk management, and operations oversight experience .
- Designated “audit committee financial expert” under SEC rules .
Equity Ownership
| Measure | Amount | Notes |
|---|---|---|
| Beneficially Owned Shares (as of 3/5/2025) | 71,309 | Less than 1% of shares outstanding |
| Options Exercisable Within 60 Days (as of 3/5/2025) | 14,008 | Included in beneficial ownership computation per SEC rules |
| Outstanding Options (12/31/2024) | 19,519 | Aggregate options held |
| Hedging Policy | Prohibited for insiders | Company prohibits hedging transactions (e.g., collars, swaps) |
| Section 16 Compliance | Compliant for 2024 | Company reports all Section 16(a) filings compliant for fiscal 2024 |
Insider Trades (recent Form 4 examples)
| Filing Date | Transaction Date | Type | Security | Qty | Price | Post-Transaction Position | Source |
|---|---|---|---|---|---|---|---|
| 2025-09-08 | 2025-09-04 | A (Award) | Dividend Equivalent Rights | 0.4173 | 0.00 | 6.5156 (DER units) | |
| 2025-09-08 | 2025-09-04 | A (Award) | Dividend Equivalent Rights | 0.8546 | 0.00 | 5.8691 (DER units) | |
| 2025-03-04 | 2025-02-28 | M (Exempt) | Common Stock | 1 | 0.00 | 57,301 (shares) | |
| 2025-03-04 | 2025-02-28 | M (Exempt) | Dividend Equivalent Rights | 1 | 0.00 | 3.0099 (DER units) |
These examples indicate periodic equity awards/adjustments (DERs) and exempt option-related transactions; no related-party transactions were disclosed in the proxy .
Governance Assessment
- Strengths: O’Connor brings deep audit and financial oversight experience as Audit Chair and SEC-designated audit committee financial expert, enhancing Board effectiveness in financial reporting, auditor oversight, and internal control monitoring . Independence affirmed; attendance thresholds met; executive sessions of independent directors occur annually, supporting independent oversight .
- Alignment: Director compensation includes both cash and meaningful equity (options, RSUs, PSUs), creating alignment with shareholder outcomes; 2024 say-on-pay support >96% suggests positive investor sentiment on compensation governance .
- Watch items:
- Combined CEO/Chair and no lead independent director reduces counterbalance to management; investors often monitor Audit Chair independence and engagement as a partial offset .
- Board diversity concerns impacted 2024 voting on another director, and the Board explicitly cited lack of racial/ethnic diversity in explaining a withhold vote outcome; continued diversity progress may be an investor focus area .
- Ensure continued adherence to hedging prohibitions and clawback policy compliance; company-level policies exist and cover executives (clawback) while insiders are prohibited from hedging .
No related-party transactions were disclosed with directors for 2024; committee memberships are fully independent, and Audit Committee members meet heightened independence standards .